| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514743000 | Halogenated hydrocarbon DOAI | 18 |
| 20090018215 | Fumigant for wood parasitic nematodes and wood fumigation method - The present invention provides a fumigant for wood parasitic nematodes comprising methyl iodide dissolved in liquefied carbon dioxide, in place of methyl bromide the use of which is globally regulated as ozone depleting substance or a fumigant using methyl iodide dissolved in liquefied carbon dioxide in combination with one or more compounds selected from the group consisting of sulfuryl fluoride, methyl isothiocyanate, phosphine, ethylene oxide, carbonyl sulfide and propylene oxide, and a fumigation method for killing wood parasitic nematodes by using said fumigant. | 01-15-2009 |
| 20140329912 | CONTRACEPTIVE COMPOSITIONS AND METHODS OF CONTRACEPTION - Compositions and methods for contraception are disclosed that use 1-bromopropane. | 11-06-2014 |
| 514744000 | Unsaturated aliphatic compound | 4 |
| 20110245350 | PROCESSES FOR PRODUCING AND COMPOSITIONS COMPRISING 2,3,3,3-TETRAFLUOROPROPENE AND/OR 1,2,3,3- TETRAFLUOROPROPENE - A process is disclosed for making CF | 10-06-2011 |
| 20130217784 | COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINS AND METHODS AND SYSTEMS USING SAME - Disclosed are the use of fluorine substituted olefins, including tetra- and penta-fluoropropenes, in a variety of applications, including in methods of depositing catalyst on a solid support, methods of sterilizing articles, cleaning methods and compositions, methods of applying medicaments, fire extinguishing/suppression compositions and methods, flavor formulations, fragrance formulations and inflating agents. | 08-22-2013 |
| 20150018429 | AZEOTROPE-LIKE COMPOSITIONS OF CIS-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE - This invention relates to azeotrope-like compositions, methods and systems having utility in numerous applications, and in particular, uses for azeotrope-like compositions comprising effective amounts of the compound cis-1,1,1,4,4,4-hexafluoro-2-butene (Z-HFO-1336mzzm), which has the following structure: | 01-15-2015 |
| 514746000 | Plural halogenated hydrocarbon compounds | 1 |
| 20150065585 | Azeotrope-Like Compositions Of Tetrafluoropropene And Hydrofluorocarbons - Provided are azeotrope-like compositions comprising tetrafluoropropene and hydrofluorocarbons and uses thereof, including use in refrigerant compositions, refrigeration systems, blowing agent compositions, and aerosol propellants. | 03-05-2015 |
| 514747000 | Carbocyclic | 3 |
| 514748000 | Two benzene rings directly attached to an acyclic hydrocarbon or acyclic halogenated hydrocarbon (e.g., D.D.T., etc.) | 2 |
| 514750000 | With organic ether or -OH containing compound non-DOAI | 2 |
| 20130317117 | SELF MICRO-EMULSIFYING DRUG DELIVERY SYSTEM WITH INCREASED BIOAVAILABILITY - The invention provides a formulation comprising (a) a drug that is poorly water-soluble, (b) at least one surfactant, and (c) at least one polar lipid, wherein the formulation is substantially free of a polar solvent, as well as methods of preparing the formulation and methods of increasing the bioavailability of a drug using the formulation. | 11-28-2013 |
| 20150320864 | SELF MICRO-EMULSIFYING DRUG DELIVERY SYSTEM WITH INCREASED BIOAVAILABILITY - The invention provides a formulation comprising (a) a drug that is poorly water-soluble, (b) at least one surfactant, and (c) at least one polar lipid, wherein the formulation is substantially free of a polar solvent, as well as methods of preparing the formulation and methods of increasing the bioavailability of a drug using the formulation. | 11-12-2015 |
| 514755000 | Polycyclo ring system | 1 |
| 514756000 | Bicyclo | 1 |
| 20100267842 | Emulsions of Perfluorocarbons - The subject application provides for an emulsion comprising an amount of a perfluorocarbon liquid dispersed as particles within, a continuous liquid phase, wherein the dispersed particles have a monomodal particle size distribution and uses thereof. The subject application also provides for a method of manufacturing a perfluorocarbon emulsion, a process for preparing a pharmaceutical product containing a PFC emulsion and a process for validating a batch of an emulsion for pharmaceutical use. | 10-21-2010 |
| 514757000 | Two or more halogenated hydrocarbons | 2 |
| 20100298445 | Optimized Fluorocarbon Emulsions for Blood Substitutes and Other Therapeutic Uses - The present invention is directed to a stable fluorocarbon emulsion having a continuous aqueous phase and discontinuous fluorocarbon phase comprising two fluorocarbons and surprisingly demonstrates that perfluorodecyl bromide is as effective in stabilizing perfluorooctyl bromide emulsions of certain concentrations than much more highly concentrated perfluorooctyl bromide/perfluorodecyl bromide emulsions without the significant problems experienced in higher concentrated emulsions such as longer organ retention times, formation of PFDB crystals, larger emulsion particles, manufacturing problems and inability of repeat dosing inherent with higher concentrations of perfluorodecyl bromide. | 11-25-2010 |
| 20110144216 | COMPOSITIONS AND USES OF CIS-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE - This invention relates to compositions, methods and systems having utility in numerous applications, and in particular, uses for compositions containing the compound cis-1,1,1,4,4,4-hexafluoro-2-butene (Z-HFO-1336mzzm), which has the following structure: | 06-16-2011 |
| 514759000 | Fluorine as only halogen | 7 |
| 20080227870 | Carcinogen Solvents in Reducing the Carcinogen Concentration of Cells - The present invention describes biologically compatible inert perfluorocarbon liquids capable of removing carcinogens from cells and thereby reducing the risk of cancerous cell transformation. This invention can be used to reduce the build-up of carcinogens, and thus be used as prophylactic medicaments in reducing the risk of chemically induced cancerous cell transformation and thus cancer. These liquids can be used as medicaments applied to any organ of the body; such an application would reduce the build-up of carcinogenic chemicals within cells of that organ and as such can be used to reduce the risk of a variety of cancers produced through chemical carcinogenesis. Such cancers include lung cancer, stomach cancer, rectal cancer, and certain types of skin cancer. | 09-18-2008 |
| 20080249188 | METHODS AND DEVICES FOR NON-INVASIVE CEREBRAL AND SYSTEMIC COOLING - A method for cerebral and systemic cooling by providing a nebulized liquid having a boiling point of 38-300° C. The nebulized liquid is delivered as a mist or a spray via the nasal and/or oral cavities of a patient. The mist causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis. Compositions and medical devices for cerebral and systemic cooling are also provided. Cooling assemblies, and methods of use, are also provided that include flexible balloon assemblies that are inserted to various locations in a patient's body. The flexible balloons are then infused with a liquid having a temperature between about −20° C. and about 37° C. The flexible balloon assemblies can be inserted into the nasal cavity, oral cavity, throat, stomach, and other locations to effect cerebral cooling. | 10-09-2008 |
| 20100093873 | Methods of improving therapy of perfluorocarbons (PFC) - This invention describes a novel, two-step method for administering PFC. The first step is designed to block the RES by administration of empty, small, liposomal vesicles (ESV) that are rapidly and preferentially engulfed by macrophages, thereby inhibiting their phagocytosis of subsequently infused PFC emulsions. The second step is the subsequent injection of PFC. ESV are devoid of materials that interfere with the macrophage's metabolic processes and do not impair their ability to clear the circulation of pathogenic organisms. Inhibition of the removal of PFC from the blood stream by the RES will achieve increased circulating PFC, enhanced binding and transport of oxygen throughout the blood stream and consequential reduction of undesirable consequences such as organomegaly and cytokine toxicity. | 04-15-2010 |
| 20110230566 | PERFLUOROCARBON EYE CREAM FORMULATIONS - Disclosed are perfluorocarbon compositions for cosmetic applications, in particular, for application to the periocular skin, and methods for using the same. | 09-22-2011 |
| 20130096204 | Buffered Oxygen Therapeutic - An oxygen therapeutic composition, comprising a perfluorocarbon material, a viscosity modifier, a buffer, wherein the buffer stabilizes a pH of the composition at between about 6.5 to about 7.5, and wherein the composition comprises a viscosity of about 2.0 to about 3.5 mPas, and wherein the fluorocarbon has a boiling point of about 4 degrees Celsius to about 60 degrees Celsius. | 04-18-2013 |
| 20140371329 | Buffered Oxygen Therapeutic - An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer. | 12-18-2014 |
| 20180021266 | Buffered Oxygen Therapeutics | 01-25-2018 |
